StreetInsider.com News Articles

Phathom Pharmaceuticals (PHAT) PT Lowered to $16 at Jefferies

Wed, 14 Oct 2026 04:53:21 -0400

Jefferies analyst Glen Santangelo lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $16.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "Q3 should be in-line vs cons. PHAT had a tough year, but we really like the 2027 setup. Despite cons #s looking high, $500M cap suggests the buyside is way below already, and 2027 guidance should be a clearing event. Further, PHAT has a very (+) risk/reward into the competitor PCAB PDUFA in Jan 2027. Even if approved, two PCABs in the market should grow awareness and penetration for both + PHAT's salesforce will likely be

Phathom Pharmaceuticals (PHAT) PT Lowered to $16 at Jefferies

Wed, 14 Oct 2026 04:53:21 -0400

Jefferies analyst Glen Santangelo lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $16.00 (from $20.00) while maintaining a Buy rating.

Phathom data projects vonoprazan cost-effective vs. PPIs for GERD

Mon, 12 Oct 2026 08:03:29 -0400

Phathom Pharmaceuticals (Nasdaq: PHAT) presented new cost-effectiveness and clinical data for its drug VOQUEZNA (vonoprazan) at the American College of Gastroenterology's 2026 Annual Scientific Meeting in Nashville, Tennessee, held October 9–14.

A predictive Markov model analyzed lifetime clinical and economic outcomes of VOQUEZNA versus proton pump inhibitors (PPIs) in commercially insured U.S. adults with Erosive GERD, starting at a mean age of 51.3 years. The model projected that VOQUEZNA would result in fewer downstream complications, such as esophageal adenocarcinoma and related deaths, compared with PPIs.

At an estimated net price, the model projected healthcare savings for VOQUEZNA over PPIs in both the

Phathom data projects vonoprazan cost-effective vs. PPIs for GERD

Mon, 12 Oct 2026 08:03:29 -0400

At an estimated net price, the model projected healthcare savings for VOQUEZNA over PPIs in both the

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

Mon, 12 Oct 2026 08:00:00 -0400

New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream complications
Additional Phathom-sponsored data highlight VOQUEZNA treatment effect across BMI subgroups in Non-Erosive GERD and real-world patient characteristics
Vonoprazan was also the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, spanning GERD, H. pylori eradication, and other gastrointestinal conditions

FLORHAM PARK, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

Mon, 12 Oct 2026 08:00:00 -0400

New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream complications
Additional Phathom-sponsored data highlight VOQUEZNA treatment effect across BMI subgroups in Non-Erosive GERD and real-world patient characteristics
Vonoprazan was also the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, spanning GERD, H. pylori eradication, and other gastrointestinal conditions

FLORHAM PARK, N.J., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,

Form 4 Phathom Pharmaceuticals, For: Oct 06 Filed by: Narula Sanjeev

Thu, 08 Oct 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20261008/27167818.html

Phathom to present Voquezna data at ACG 2026 meeting

Thu, 08 Oct 2026 08:00:40 -0400

Phathom Pharmaceuticals (Nasdaq: PHAT) will present three scientific posters on its drug Voquezna (vonoprazan) at the American College of Gastroenterology 2026 Annual Scientific Meeting, held October 9-14 in Nashville, Tennessee.

The presentations will cover new analyses related to Gastroesophageal Reflux Disease (GERD), including a post hoc analysis of Voquezna efficacy across body mass index subgroups in patients with non-erosive GERD, a retrospective analysis of real-world patient characteristics, and a Markov model examining cost-effectiveness of Voquezna compared with proton pump inhibitors (PPIs) in erosive esophagitis.

The BMI subgroup poster is scheduled for October 11, followed by the real-world patient characteristics poster on October

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Thu, 08 Oct 2026 08:00:00 -0400

Three scientific presentations will highlight new analyses of VOQUEZNA^® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis

FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee.

Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA^® (vonoprazan) in Gastroesophageal Reflux Disease

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Thu, 08 Oct 2026 08:00:00 -0400

Three scientific presentations will highlight new analyses of VOQUEZNA^® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis

Phathom will present three scientific posters featuring new data and analyses for VOQUEZNA^® (vonoprazan) in Gastroesophageal Reflux Disease

Form 8-K Phathom Pharmaceuticals, For: Sep 29

Tue, 29 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260929/27123118.html

Phathom starts Phase 3 trial of Voquezna for on-demand GERD use

Tue, 29 Sep 2026 08:00:28 -0400

Phathom Pharmaceuticals (Nasdaq: PHAT) announced the start of patient screening for pHalcon-NERD-302, a Phase 3 clinical study evaluating an as-needed dosing regimen of its drug VOQUEZNA (vonoprazan) in adults with Non-Erosive Gastroesophageal Reflux Disease (NERD). Topline results are expected in the first quarter of 2028.

The multicenter, randomized, double-blind, placebo-controlled study will enroll approximately 500 adults who report heartburn at least four days per week, across roughly 80 sites in the U.S. After a four-week open-label run-in period with VOQUEZNA 10 mg once daily, eligible patients will be randomized to receive either VOQUEZNA 10 mg or placebo on an as-needed basis

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Tue, 29 Sep 2026 08:00:00 -0400

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data
Topline results expected in the first quarter of 2028
pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) are not currently approved in the U.S.

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Tue, 29 Sep 2026 08:00:00 -0400

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data
Topline results expected in the first quarter of 2028
pHalcon-NERD-302, if successful, is intended to support a potential VOQUEZNA label expansion to include as-needed treatment of heartburn episodes in patients with Non-Erosive GERD, a treatment regimen of interest to patients for which proton pump inhibitors (PPIs) are not currently approved in the U.S.

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT),

Leerink Starts Phathom Pharmaceuticals (PHAT) at Market Perform

Wed, 09 Sep 2026 06:11:09 -0400

Leerink analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Market Perform rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.

Shares of Phathom Pharmaceuticals closed at $9.43 yesterday.

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:

2026 Cantor Global Healthcare Conference in New York, NY
Date: Wednesday, September 9, 2026
Fireside Chat: 10:55 am EDT
Management to participate in one-on-one meetings throughout the conference

H.C. Wainwright 28th Annual Global Investment Conference in New York, NY
Date: Tuesday, September 15, 2026
Fireside Chat: 3:30 pm

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference in New York, NY
Date: Tuesday, September 15, 2026
Fireside Chat: 3:30 pm

Phathom Pharmaceuticals (PHAT) PT Lowered to $14 at Barclays

Mon, 17 Aug 2026 04:53:17 -0400

Barclays analyst Glen Santangelo lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $14.00 (from $18.00) while maintaining a Overweight rating.

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Fri, 31 Jul 2026 06:47:30 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $26.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst commented: "We believe the company delivered for the quarter based on: (1) record 2Q26 revenue reflecting 88% growth YoY from 2Q25, and 27% over the prior quarter, discussed below; (2) operating profitability excluding stock-based compensation for the quarter; (3) announced new plans to initiate a registrational Phase 3 program for vonoprazan in the as-needed on-demand treatment on non-erosive GERD (NERD) patients, notably where traditional PPI therapies lack approval and the necessary efficacy profile; (4) completed enrollment for the Phase 2 pHalcon-EoE-201

Phathom Pharmaceuticals (PHAT) PT Lowered to $22 at Guggenheim

Thu, 30 Jul 2026 13:04:27 -0400

(Updated - July 30, 2026 1:04 PM EDT)

Guggehneim analyst Yatin Suneja lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $22.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "PHAT has delivered robust Q/Q Voquezna TRx and revenue growth, exceeding consensus expectations, as well as achieving operational profitability for the first time in the company's history. Despite this momentum, mgmt has lowered FY26 revenue guidance marginally to $310-325MM (From $320-345MM), citinglogistical issues with prescribing and prior authorization process which requires a bit more education. While there is no coverage or demand issue, mgmt noted some emergence of increased

Phathom Pharmaceuticals (PHAT) PT Lowered to $22 at Guggenheim

Thu, 30 Jul 2026 13:04:27 -0400

(Updated - July 30, 2026 1:04 PM EDT)

Guggehneim analyst Yatin Suneja lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $22.00 (from $25.00) while maintaining a Buy rating.

Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 19c

Thu, 30 Jul 2026 07:36:26 -0400

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $74.27 million versus the consensus estimate of $73.98 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

Form 10-Q Phathom Pharmaceuticals, For: Jun 30

Thu, 30 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26838543.html

Form 10-Q Phathom Pharmaceuticals, For: Jun 30

Thu, 30 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26838543.html

Form 8-K Phathom Pharmaceuticals, For: Jul 30

Thu, 30 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26838528.html